Internal Medicine

Initial data show similar efficacy but different costs among injectable insulin treatments for patients who fail oral antidiabetic drugs.

A recent study suggests that skipping breakfast in overweight women may lead to insulin resistance.

Researchers recommended long-term surveillance of patients with hyponatremia on discharge.

Dr. Lim discusses the challenges of diagnosing and treating lupus, the tools and resources offered by the Lupus Initiative, and the impact of unconscious bias on care.

Merck & Co. has ceased development of its experimental therapy for Parkinson's disease after the drug failed to show superiority to placebo in initial data from a series of phase III clinical trials.

A high-potency probiotic supplement that mimics the effect of morphine in the gut may reduce the development of visceral pain in irritable bowel syndrome (IBS).

Approved by the US FDA in August 2012, Gilead's Stribild is indicated to treat human immunodeficiency virus type 1 (HIV-1) infection in adults who have no prior experience with antiretroviral therapy.

Results of a recent clinical trial by researchers at the Department of Rehabilitation Medicine in the Affiliated Tenth People's Hospital of Tongji University, in Shanghai, China, have deemed locally injected methylcobalamin more effective than its orally administered counterpart as a treatment for subacute herpetic neuralgia.

As irritable bowel syndrome (IBS) remains a complicated condition to treat with an etiology that's still unknown, it's difficult for physicians to find the best proven therapies among new remedies and the variety of pharmacological and nondrug options they have been trying for years.

While it's already clinically understood that most patients with Crohn's disease suffer a recurrence following an intestinal resection, researchers have not evaluated the best strategy to prevent the disease from recurring.

Patients taking linaclotide experience clinically meaningful improvement in abdominal and bowel symptoms, which closely correlate with the US Food and Drug Administration's new criteria for irritable bowel syndrome with constipation (IBS-C).

Esophageal pH monitoring is more cost effective than the long-term use of proton-pump inhibitors (PPIs), since it can help rule out gastroesophageal reflux diseases (GERD) and avoid the unneeded costs associated with prolonged medication therapy.

While it's important for nutrition and an integral part of patients' lives, food also plays a role in functional gastrointestinal disorders such as irritable bowel syndrome (IBS).

Andrew J. Muir, MD, MHS, said having more antiviral hepatitis C drugs in the pipeline could spur more people to accept treatment and improve patient outcomes.

Presenters at Digestive Disease Week 2013, held May 18-21, 2013, in Orlando, Fla., differed on the risks of surgical complications from the use of biologic agents.

The American College of Rheumatology recently announced a new easy-to-use curriculum and tools aimed to help medical professionals advance the diagnosis, treatment, and management of lupus.

The US Food and Drug Administration (FDA) today expanded approval of Simponi (golimumab) to treat moderate to severe ulcerative colitis, a chronic inflammatory bowel disease (IBD) that affects some 620,000 Americans.

Study supports the current practice of post-surgery H. pylori eradication in patients with perforated peptic ulcers.

In light of issues concerning opioid misuse running parallel to the tenfold increase of prescription opioid use over the past 20 years, a team of researchers have developed an ongoing study examining results of a pilot program aimed at reducing patients' use of pain medications.

Genome studies provide clues about variation in individual risk for H. pylori infection.

Citing an increased risk of liver injury observed in recent clinical trials, the US Food and Drug Administration (FDA) has limited Samsca (tolvaptan) treatment to 30 days and recommended the oral selective vasopressin V2-receptor antagonist be discontinued in patients with signs of liver disease or symptoms of liver injury.

The US Food and Drug Administration (FDA) today approved Kcentra [prothrombin complex concentrate (human)] for the urgent reversal of anticoagulation induced by vitamin K antagonist (VKA) therapies such as warfarin in adult patients with acute major bleeding.

In diagnosing a patient with type 2 diabetes, an endocrinologist or primary care physician may struggle with developing healthy treatment targets when comorbid conditions like obesity and hypoglycemia are at play.

After noticing the ample adverse effects of second-line Helicobacter pylori eradication treatments that utilize tetracycline, furazolidone and proton-pump inhibitors, one group of gastroenterologists set to work adding a probiotic compound to the regimen in an attempt to increase the stomach bacteria's eradication rate while curbing those unwanted effects.

The advent of accountable care organizations, bundled payments, and other reforms under the Affordable Care Act has steered the focus of health care delivery from quantity to quality, but where exactly do pain medicine providers fit into the new value-based care model, and how can it benefit their patients?

Approved by the FDA nearly four years ago, Otsuka Group's once-daily Samsca (tolvaptan tablets) is indicated to raise serum sodium levels in nonurgent patients with hyponatremia.

Approved by the FDA in September 2012, Genzyme's Aubagio (teriflunomide tablets) is a once-daily oral treatment shown to reduce relapses, slow physical disability progression and reduce the number of brain lesions detected by magnetic resonance imaging (MRI) in patients with relapsing forms of multiple sclerosis (MS).

Compared with placebo, teriflunomide was shown to significantly reduce the occurrence of relapses with sequelae and relapses treated with corticosteroids in a post-hoc analysis of pivotal clinical trial data.

While phenotypes of multiple sclerosis (MS) are well-established, there remains heterogeneity among patients that fit existing clinical definitions.

Oral dimethyl fumarate (BG-12) is in development for the treatment of relapsing multiple sclerosis (MS), though experimental evidence already suggests it may provide anti-inflammatory and cytoprotective effects by activating the transcription factor Nrf2.